CC
MCID: CHL065
MIFTS: 64

Cholangiocarcinoma (CC)

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Cholangiocarcinoma

MalaCards integrated aliases for Cholangiocarcinoma:

Name: Cholangiocarcinoma 57 38 76 25 59 37 55 73
Cholangiocarcinoma, Susceptibility to 57 29
Intrahepatic Cholangiocarcinoma 25 73
Extrahepatic Cholangiocarcinoma 25 73
Adult Primary Cholangiocellular Carcinoma 73
Cholangiocarcinoma of Biliary Tract 25
Cholangiocellular Carcinoma 25
Chlc, Susceptibility to 57
Bile Duct Carcinoma 73
Bile Duct Cancer 59
Chlc 57
Cca 59
Cc 25

Characteristics:

Orphanet epidemiological data:

59
cholangiocarcinoma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Europe); Age of onset: Adult;

Classifications:

Orphanet: 59  
Rare hepatic diseases


External Ids:

OMIM 57 615619
Orphanet 59 ORPHA70567
ICD10 via Orphanet 34 C24.8 C24.9 C22.1 more
MESH via Orphanet 45 D001650 D018281
UMLS via Orphanet 74 C0206698 C0740277
MedGen 42 C3810156
KEGG 37 H00046

Summaries for Cholangiocarcinoma

OMIM : 57 Carcinomas of the biliary tract are aggressive malignancies, with 5-year survival of less than 10%. These carcinomas arise throughout the biliary tree and are anatomically classified as either intrahepatic or extrahepatic cholangiocarcinomas. Gallbladder carcinomas also arise from the biliary tree but have distinct natural histories compared to cholangiocarcinomas, suggesting different underlying tumor biology. Cholangiocarcinoma incidence varies widely between geographic regions, reflecting the impact of different underlying etiologies. In endemic areas, liver fluke infections by O. viverrini and Clonorchis sinensis, both group I carcinogens, represent the major risk factor for cholangiocarcinomas. In nonendemic regions, other risk factors, including choledochal cysts (603003), hepatolithiasis, and primary sclerosing cholangitis (613806), are likely contributors (summary by Chan-on et al., 2013). Overall, the majority of patients lack such identifiable risk factors (summary by Jiao et al., 2013). (615619)

MalaCards based summary : Cholangiocarcinoma, also known as cholangiocarcinoma, susceptibility to, is related to klatskin's tumor and gallbladder cancer, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Cholangiocarcinoma is MIR21 (MicroRNA 21), and among its related pathways/superpathways is MicroRNAs in cancer. The drugs Abraxane and Abstral have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and small intestine, and related phenotypes are fever and fatigue

Genetics Home Reference : 25 Cholangiocarcinoma is a group of cancers that begin in the bile ducts. Bile ducts are branched tubes that connect the liver and gallbladder to the small intestine. They carry bile, which is a fluid that helps the body digest the fats in food. Bile is produced in the liver and stored in the gallbladder before being released in the small intestine after a person eats.

Wikipedia : 76 Cholangiocarcinoma, also known as bile duct cancer, is a form of cancer that is composed of mutated... more...

Related Diseases for Cholangiocarcinoma

Diseases related to Cholangiocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 502)
# Related Disease Score Top Affiliating Genes
1 klatskin's tumor 33.7 MALAT1 MIR373
2 gallbladder cancer 30.5 AFAP1-AS1 H19 MALAT1 TUG1 UCA1
3 small cell cancer of the lung 30.3 CCAT2 MALAT1 MIR21 TUG1
4 kidney cancer 30.2 H19 MALAT1 MIR141 MIR200B MIR21
5 hepatocellular carcinoma 30.0 AFAP1-AS1 CCAT2 H19 HULC MALAT1 MIR141
6 glioblastoma 30.0 H19 MALAT1 MIR21 TUG1
7 pancreatic ductal adenocarcinoma 29.9 AFAP1-AS1 H19 MALAT1 MIR141 MIR148A MIR21
8 laryngeal squamous cell carcinoma 29.8 H19 MALAT1 MIR21 NEAT1
9 renal cell carcinoma, nonpapillary 29.8 H19 MALAT1 MIR141 TUG1 UCA1
10 lung cancer susceptibility 3 29.7 AFAP1-AS1 H19 MALAT1 MIR200B TUG1
11 atherosclerosis susceptibility 29.7 H19 HULC TUG1
12 thyroid cancer 29.7 AFAP1-AS1 H19 MALAT1 NEAT1 UCA1
13 diffuse large b-cell lymphoma 29.6 HULC MIR21 MIR320A
14 nasopharyngeal carcinoma 29.6 AFAP1-AS1 H19 HULC MALAT1 NEAT1
15 lung squamous cell carcinoma 29.5 CCAT2 SOX2-OT TUG1
16 tongue squamous cell carcinoma 29.5 AFAP1-AS1 MALAT1 MIR21 UCA1
17 bladder cancer 29.5 CCAT2 H19 HULC MALAT1 MIR21 SPRY4-IT1
18 pancreatic cancer 29.4 AFAP1-AS1 H19 HULC MALAT1 MIR148A MIR21
19 squamous cell carcinoma 29.4 CCAT2 H19 MALAT1 NEAT1 SOX2-OT SPRY4-IT1
20 cervical cancer 29.3 CCAT2 H19 HULC MALAT1 MIR21 NEAT1
21 clear cell renal cell carcinoma 29.2 CCAT2 MALAT1 MIR21 MIR320A SPRY4-IT1 TUG1
22 leukemia, acute myeloid 29.2 MALAT1 MIR204 MIR21 MIR320A TUG1 UCA1
23 oral squamous cell carcinoma 29.2 CCAT2 H19 MALAT1 MIR200B MIR204 MIR21
24 prostate cancer 29.2 CCAT2 H19 HULC MALAT1 MIR141 MIR148A
25 osteogenic sarcoma 29.2 CCAT2 H19 HULC MALAT1 NEAT1 SOX2-OT
26 lung cancer 29.2 AFAP1-AS1 CCAT2 H19 MALAT1 MIR141 MIR148A
27 gastric cancer 29.1 AFAP1-AS1 CCAT2 H19 HULC MALAT1 MIR141
28 colorectal cancer 29.0 AFAP1-AS1 CCAT2 H19 HULC MALAT1 MIR141
29 melanoma 29.0 H19 MALAT1 MIR141 MIR200B MIR204 SOX2-OT
30 ovarian cancer 28.7 AFAP1-AS1 CCAT2 H19 MALAT1 MIR141 MIR152
31 breast cancer 28.4 CCAT2 H19 MALAT1 MIR141 MIR148A MIR152
32 intrahepatic cholangiocarcinoma 12.7
33 arthrogryposis, distal, type 9 12.3
34 sarcomatous intrahepatic cholangiocarcinoma 12.2
35 mucinous intrahepatic cholangiocarcinoma 12.2
36 signet ring cell intrahepatic cholangiocarcinoma 12.1
37 clonorchiasis 11.5
38 epilepsy occipital calcifications 11.5
39 cholangitis, primary sclerosing 11.5
40 opisthorchiasis 11.4
41 bile duct cancer 11.4
42 biliary tract neoplasm 11.4
43 acrocallosal syndrome 11.3
44 familial calcium pyrophosphate deposition 11.3
45 central cord syndrome 11.2
46 congenitally corrected transposition of the great arteries 11.1
47 cholangitis 10.7
48 sclerosing cholangitis 10.6
49 hepatitis 10.5
50 hepatitis b 10.4

Graphical network of the top 20 diseases related to Cholangiocarcinoma:



Diseases related to Cholangiocarcinoma

Symptoms & Phenotypes for Cholangiocarcinoma

Clinical features from OMIM:

615619

Human phenotypes related to Cholangiocarcinoma:

59 32 (show all 9)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 59 32 occasional (7.5%) Occasional (29-5%) HP:0001945
2 fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012378
3 abdominal pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0002027
4 pruritus 59 32 frequent (33%) Frequent (79-30%) HP:0000989
5 jaundice 59 32 hallmark (90%) Very frequent (99-80%) HP:0000952
6 anorexia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002039
7 biliary tract neoplasm 59 32 hallmark (90%) Very frequent (99-80%) HP:0100574
8 acholic stools 59 32 hallmark (90%) Very frequent (99-80%) HP:0011985
9 cholangiocarcinoma 32 HP:0030153

UMLS symptoms related to Cholangiocarcinoma:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas, malaise

Drugs & Therapeutics for Cholangiocarcinoma

FDA approved drugs:

(show top 50) (show all 125)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Abraxane 18 49 PACLITAXEL Celgene October 2012
2
Abstral 18 FENTANYL (citrate) ProStrakan January 2011
3
Actiq 18 FENTANYL (citrate) Anesta Corporation November 1998
4
Adcetris 18 49 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
5
Arimidex 18 49 ANASTROZOLE AstraZeneca January 1996
6
Arranon 18 49 NELARABINE GlaxoSmithKline October 2005
7
Arzerra 18 49 OFATUMUMAB GlaxoSmithKline October 2009
8
Beleodaq 18 49 BELINOSTAT Spectrum Pharmaceuticals July 2014
9
Blincyto 18 49 BLINATUMOMAB Amgen December 2014
10
Bosulif 18 49 BOSUTINIB MONOHYDRATE Pfizer September 2012
11
Busulfex 18 49 BUSULFAN Orphan Medical February 1999
12
Campath 18 49 ALEMTUZUMAB Berlex Laboratories May 2001
13
Cervarix 18 49 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
14
Cometriq 18 49 CABOZANTINIB S-MALATE Exelixis November 2012
15
Cyramza 18 49 RAMUCIRUMAB Eli Lilly April 2014
16
Degarelix 18 49 degarelix Ferring Pharmaceuticals December of 2008
17
Elliotts B Solution 18 CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE Orphan Medical October 1996
18
Eloxatin 18 49 OXALIPLATIN Sanofi-aventis August 2002
19
Emend 18 49 APREPITANT FOSAPREPITANT DIMEGLUMINE Merck March 2003
20
Erbitux 18 49 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
21
Erivedge 18 49 VISMODEGIB Genentech January 2012
22
Farydak 18 49 PANOBINOSTAT LACTATE Novartis February 2015
23
Faslodex 18 49 FULVESTRANT AstraZeneca April 2002
24
Folotyn 18 49 PRALATREXATE Allos Therapeutics September 2009
25
Gardasil 18 49 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
26
Gilotrif 18 49 AFATINIB DIMALEATE Boehringer Ingelheim July 2013
27
Gleevec 18 49 IMATINIB MESYLATE Novartis May 2001
28
Ibrance 18 49 PALBOCICLIB Pfizer February 2015
29
Iclusig 18 49 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals December 2012
30
Imbruvica 18 49 IBRUTINIB Pharmacyclics November of 2013/February 2014
31
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
32
Iressa 18 49 GEFITINIB AstraZeneca May 2003
33
Istodax 18 49 ROMIDEPSIN Gloucester Pharmaceuticals November 2009
34
Jevtana 18 49 CABAZITAXEL sanofi aventis June 2010
35
Kadcyla 18 49 ADO-TRASTUZUMAB EMTANSINE Genentech February 2013
36
Keytruda 18 49 PEMBROLIZUMAB Merck September 2014
37
Kyprolis 18 49 CARFILZOMIB Onyx Pharmaceuticals July 2012
38
Lazanda 18 FENTANYL CITRATE Archimedes June 2011
39
Lenvima 18 49 LENVATINIB MESYLATE Eisai February 2015
40
Leukine 18 SARGRAMOSTIM Immunex on November 24, 1995/ November 1996
41
Lynparza 18 49 OLAPARIB AstraZeneca December 2014
42
Mekinist 18 49 TRAMETINIB DIMETHYL SULFOXIDE GlaxoSmithKline May of 2013
43
Miraluma Test 18 TECHNETIUM TC-99M SESTAMIBI KIT DuPont Merck Pharmaceutical Company May 1997
44
Nolvadex 18 49 TAMOXIFEN CITRATE AstraZeneca October 1998
45
Odomzo 18 49 SONIDEGIB PHOSPHATE Novartis Jul-15
46
Onsolis 18 FENTANYL CITRATE BioDelivery Sciences July 2009
47
Opdivo 18 49 NIVOLUMAB Bristol-Myers Squibb March 2015/ December 2014, March 2015
48
Perjeta 18 49 PERTUZUMAB Genentech June 2012
49
Premarin 18 ESTROGENS CONJUGATED Wyeth July of 2003
50
Provenge 18 49 sipuleucel-T Dendreon May 2010

Drugs for Cholangiocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 313)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
2
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 53608-75-6
3
Isoflurane Approved, Vet_approved Phase 4,Not Applicable 26675-46-7 3763
4
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
5
Desflurane Approved Phase 4,Not Applicable 57041-67-5 42113
6
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
7
Meperidine Approved Phase 4 57-42-1 4058
8
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
9
Etomidate Approved Phase 4 33125-97-2 667484 36339
10
Bilirubin Phase 4,Not Applicable 635-65-4 5280352
11 Analgesics Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
12 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 1,Phase 2
13 Cyclooxygenase Inhibitors Phase 4
14 Cyclooxygenase 2 Inhibitors Phase 4
15 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2
16 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
17 pancreatin Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Antirheumatic Agents Phase 4,Phase 1,Phase 2
20 Analgesics, Non-Narcotic Phase 4,Phase 1,Phase 2
21 arginine Phase 4
22 Omega 3 Fatty Acid Phase 4
23 Anesthetics, Inhalation Phase 4,Not Applicable
24 Anesthetics, General Phase 4,Phase 3,Not Applicable
25 Liver Extracts Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 Central Nervous System Depressants Phase 4,Phase 3,Not Applicable
27 Anesthetics Phase 4,Phase 3,Not Applicable
28 Platelet Aggregation Inhibitors Phase 4
29 Cola Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
30
Bismuth Phase 4,Phase 3 7440-69-9 16682734 105143
31 GABA Modulators Phase 4,Not Applicable
32 GABA Agents Phase 4,Not Applicable
33 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
34 Hypnotics and Sedatives Phase 4,Not Applicable
35 Anti-Anxiety Agents Phase 4,Phase 3
36 Adjuvants, Anesthesia Phase 4,Phase 3
37 Analgesics, Opioid Phase 4,Phase 3,Not Applicable
38 Anesthetics, Intravenous Phase 4,Phase 3,Not Applicable
39 Narcotics Phase 4,Phase 3,Not Applicable
40 Tranquilizing Agents Phase 4,Phase 3
41 Psychotropic Drugs Phase 4,Phase 3
42
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
43
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
44
Trioxsalen Approved Phase 2, Phase 3,Phase 3,Not Applicable 3902-71-4 5585
45
Fluorouracil Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 51-21-8 3385
46
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 68538-85-2
47
leucovorin Approved Phase 2, Phase 3,Phase 3,Phase 1 58-05-9 6006 143
48
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
49
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3 128-13-2 31401
50
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345

Interventional clinical trials:

(show top 50) (show all 493)
# Name Status NCT ID Phase Drugs
1 Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent Unknown status NCT00746538 Phase 4
2 Preoperative Biliary Drainage for Resectable Hilar Cholangiocarcinoma Unknown status NCT00797121 Phase 4
3 Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
4 Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Unknown status NCT01256047 Phase 4
5 Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
6 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
7 Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture Unknown status NCT01125865 Phase 4
8 Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Hilar Cholangiocarcinoma Completed NCT00721175 Phase 4
9 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
10 Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
11 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
12 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
13 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
14 Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma Unknown status NCT02108145 Phase 2, Phase 3
15 Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma Unknown status NCT02548195 Phase 3 oxaliplatin and gemcitabine;capecitabine
16 Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma Unknown status NCT01739465 Phase 2, Phase 3
17 Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures Unknown status NCT00653978 Phase 3
18 Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
19 S-1 and Photodynamic Therapy in Cholangiocarcinoma Completed NCT00869635 Phase 3 S-1 Chemotherapy
20 Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
21 Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery Completed NCT00513539 Phase 3 porfimer sodium
22 Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
23 Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
24 Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
25 Trial of High-dose Urso in Primary Sclerosing Cholangitis Completed NCT00059202 Phase 2, Phase 3 Ursodeoxycholic Acid
26 Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms Completed NCT01640522 Phase 3
27 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
28 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
29 A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302) Recruiting NCT03656536 Phase 3 Pemigatinib;Gemcitabine;Cisplatin
30 Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma Recruiting NCT02773485 Phase 3 Systemic chemotherapy
31 SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma Recruiting NCT02807181 Phase 2, Phase 3 Cisplatin-gemcitabine
32 Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) Recruiting NCT02989857 Phase 3 AG-120;AG-120 matched placebo
33 Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma Recruiting NCT03086993 Phase 2, Phase 3 Cisplatin and Gemcitabine
34 A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma Recruiting NCT03251443 Phase 3 Apatinib
35 Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma Recruiting NCT01755013 Phase 2, Phase 3
36 Bortezomib in Intrahepatic Cholangiocellular Carcinoma Recruiting NCT03345303 Phase 3 Bortezomib
37 HAIC Versus Systemic Chemotherapy for Unresectable ICC Recruiting NCT03771846 Phase 3 gemcitabine, oxaliplatin , fluorouracil, and leucovorin;gemcitabine and oxaliplatin
38 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
39 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Recruiting NCT02798510 Phase 3 capecitabine;gemcitabine
40 Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours Recruiting NCT02591030 Phase 2, Phase 3 GEMCIS;mFolfirinox
41 Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma Recruiting NCT01470443 Phase 3 Oxaliplatin;Oxaliplatin
42 Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection Recruiting NCT03779035 Phase 3 Gemcitabine;Capecitabine
43 Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
44 Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy Recruiting NCT02853474 Phase 3
45 Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L Recruiting NCT02232490 Phase 3
46 Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma Active, not recruiting NCT02482454 Phase 2, Phase 3
47 Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers Active, not recruiting NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
48 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Active, not recruiting NCT02349412 Phase 3
49 Study of Oral Infigratinib in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations Not yet recruiting NCT03773302 Phase 3 BGJ398;Gemcitabine;Cisplatin
50 Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS) Terminated NCT02082522 Phase 3 Photodynamic therapy-Photofrin;Chemotherapy regimen

Search NIH Clinical Center for Cholangiocarcinoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Cholangiocarcinoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Cholangiocarcinoma:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Cholangiocarcinoma:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 23904171 21498393 22996367 19304471 22555974 15800326 23650429 21325070 24218514 8170938 12242449

Genetic Tests for Cholangiocarcinoma

Genetic tests related to Cholangiocarcinoma:

# Genetic test Affiliating Genes
1 Cholangiocarcinoma, Susceptibility to 29

Anatomical Context for Cholangiocarcinoma

MalaCards organs/tissues related to Cholangiocarcinoma:

41
Liver, Lymph Node, Small Intestine, T Cells, Thyroid, Breast, Neutrophil

Publications for Cholangiocarcinoma

Articles related to Cholangiocarcinoma:

(show top 50) (show all 3446)
# Title Authors Year
1
Impact of microvascular invasion on clinical outcomes after curative-intent resection for intrahepatic cholangiocarcinoma. ( 30466151 )
2019
2
Specific prognostic factors in hepatitis B virus-related and non-hepatitis B virus-related intrahepatic cholangiocarcinoma after macroscopic curative resection. ( 30480811 )
2019
3
Preoperative drainage for perihilar cholangiocarcinoma. ( 30527574 )
2019
4
Preoperative drainage for perihilar cholangiocarcinoma. ( 30527575 )
2019
5
Preoperative drainage for perihilar cholangiocarcinoma - Authors' reply. ( 30527576 )
2019
6
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments. ( 30528800 )
2019
7
Mouse Model for Hepatocellular Carcinoma and Cholangiocarcinoma Originated from Mature Hepatocytes. ( 30536104 )
2019
8
Mouse Model for Cholangiocarcinoma from Peribiliary Glands. ( 30536105 )
2019
9
S100A11 promotes cell proliferation via P38/MAPK signaling pathway in intrahepatic cholangiocarcinoma. ( 30182496 )
2019
10
Enhancement Patterns of Intrahepatic Cholangiocarcinoma on Contrast-Enhanced Ultrasound: Correlation with Clinicopathologic Findings and Prognosis. ( 30292461 )
2019
11
Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma through recruiting MAPK1 and mediating Ser675 phosphorylation of I^-Catenin. ( 29415992 )
2018
12
Induction of differentiation of intrahepatic cholangiocarcinoma cells to functional hepatocytes using an organoid culture system. ( 29434290 )
2018
13
Sirtuin7 has an oncogenic potential via promoting the growth of cholangiocarcinoma cells. ( 29438839 )
2018
14
MicroRNA-26b-5p regulates cell proliferation, invasion and metastasis in human intrahepatic cholangiocarcinoma by targeting S100A7. ( 29387225 )
2018
15
Enhanced expression of lncRNA TP73-AS1 predicts adverse phenotypes for cholangiocarcinoma and exerts oncogenic properties in vitro and in vivo. ( 29966969 )
2018
16
An interesting case of inflammatory myofibroblastic tumor presenting as cholangiocarcinoma. ( 29705678 )
2018
17
Characterization and prognostic significance of mortalin, Bcl-2 and Bax in intrahepatic cholangiocarcinoma. ( 29434920 )
2018
18
Opisthorchiasis-Induced Cholangiocarcinoma: How Innate Immunity May Cause Cancer. ( 29907253 )
2018
19
Challenges of surgical management of intrahepatic cholangiocarcinoma. ( 29911912 )
2018
20
Let-7c inhibits cholangiocarcinoma growth but promotes tumor cell invasion and growth at extrahepatic sites. ( 29445149 )
2018
21
Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib. ( 29251327 )
2018
22
Impact of viral hepatitis B status on outcomes of intrahepatic cholangiocarcinoma: a meta-analysis. ( 29947010 )
2018
23
Salinomycin inhibits cholangiocarcinoma growth by inhibition of autophagic flux. ( 29423070 )
2018
24
Thermal ablation of intrahepatic cholangiocarcinoma: Safety, efficacy, and factors affecting local tumor progression. ( 29869103 )
2018
25
Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin. ( 29874985 )
2018
26
Role of palliative radiotherapy in unresectable intrahepatic cholangiocarcinoma: population-based analysis with propensity score matching. ( 29942151 )
2018
27
Comparing Clonality Between Components of Combined Hepatocellular Carcinoma and Cholangiocarcinoma by Targeted Sequencing. ( 29976634 )
2018
28
Fyn knockdown inhibits migration and invasion in cholangiocarcinoma through the activated AMPK/mTOR signaling pathway. ( 29434909 )
2018
29
Role of fluorescence in situ hybridization in diagnosing cholangiocarcinoma in indeterminate biliary strictures. ( 28543841 )
2018
30
Serum tumor markers enhance the predictive power of the AJCC and LCSGJ staging systems in resectable intrahepatic cholangiocarcinoma. ( 29887261 )
2018
31
Differential diagnosis of cholangiocarcinoma and IgG4-related sclerosing cholangitis by fluorescence inA situ hybridization using transpapillary forceps biopsy specimens. ( 29532638 )
2018
32
Unique Responses of Hepatocellular Carcinoma and Cholangiocarcinoma Cell Lines toward Cantharidin and Norcantharidin. ( 29937938 )
2018
33
Tumor-associated macrophages recruited by periostin in intrahepatic cholangiocarcinoma stem cells. ( 29805605 )
2018
34
Small intestinal obstruction due to the metastasis of intrahepatic cholangiocarcinoma: A case report. ( 29561438 )
2018
35
Preoperative Biliary Drainage Is Associated with Increased Complications After Liver Resection for Proximal Cholangiocarcinoma. ( 29980975 )
2018
36
<sup>18</sup>F-FDG PET/CT may be a suitable method for preoperative diagnosis and evaluation of Chinese older patients with hilar cholangiocarcinoma. ( 29976141 )
2018
37
<i>In Vivo</i> Study of Natural Killer (NK) Cell Cytotoxicity Against Cholangiocarcinoma in a Nude Mouse Model. ( 29936458 )
2018
38
<sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Imaging of Inferior Vena Cava Tumor Thrombus Extending into the Right Atrium in a Patient with Cholangiocarcinoma Treated with <sup>90</sup>Y-Microspheres. ( 29962728 )
2018
39
Microvessel density and angiogenesis in primary hepatic malignancies: Differential expression of CD31 and VEGFR-2 in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. ( 29935812 )
2018
40
Prognostic comparison of the 7th and 8th editions of the American Joint Commission on Cancer staging system for intrahepatic cholangiocarcinoma. ( 29450978 )
2018
41
A novel prognostic biomarker for cholangiocarcinoma: circRNA Cdr1as. ( 29424892 )
2018
42
Potential role of HIF-1-responsive microRNA210/HIF3 axis on gemcitabine resistance in cholangiocarcinoma cells. ( 29953500 )
2018
43
RA190, a Proteasome Subunit ADRM1 Inhibitor, Suppresses Intrahepatic Cholangiocarcinoma by Inducing NF-KB-Mediated Cell Apoptosis. ( 29913454 )
2018
44
Diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. ( 29781738 )
2018
45
Upregulation of long nona89coding RNA CCAT2 indicates a poor prognosis and promotes proliferation and metastasis in intrahepatic cholangiocarcinoma. ( 29393466 )
2018
46
The expression and clinicopathological role of CDX2 in intrahepatic cholangiocarcinoma. ( 29862152 )
2018
47
Nab-paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma. ( 29963132 )
2018
48
B7-H3 expression and its correlation with clinicopathologic features, angiogenesis, and prognosis in intrahepatic cholangiocarcinoma. ( 29696716 )
2018
49
Current Perspectives on Opisthorchiasis Control and Cholangiocarcinoma Detection in Southeast Asia. ( 29765958 )
2018
50
The diagnostic value of five serum tumor markers for patients with cholangiocarcinoma. ( 29438681 )
2018

Variations for Cholangiocarcinoma

Cosmic variations for Cholangiocarcinoma:

9 (show top 50) (show all 1681)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6974042 ZFHX3 biliary tract,bile duct,carcinoma,NS c.6964C>T p.R2322* 16:72795718-72795718 11
2 COSM6957143 ZFHX3 biliary tract,bile duct,carcinoma,NS c.3529+1G>A p.? 16:72829778-72829778 11
3 COSM6928728 YAP1 biliary tract,bile duct,carcinoma,NS c.434C>G p.T145S 11:102114256-102114256 11
4 COSM6986174 XPO1 biliary tract,bile duct,carcinoma,NS c.273G>T p.W91C 2:61522639-61522639 11
5 COSM6975271 XPO1 biliary tract,bile duct,carcinoma,NS c.729G>T p.E243D 2:61498703-61498703 11
6 COSM6985358 XPO1 biliary tract,bile duct,carcinoma,NS c.338C>T p.T113M 2:61502274-61502274 11
7 COSM6923580 TSC1 biliary tract,bile duct,carcinoma,NS c.2551C>T p.Q851* 9:132900789-132900789 11
8 COSM4172016 TSC1 biliary tract,bile duct,carcinoma,NS c.737+1G>A p.? 9:132921362-132921362 11
9 COSM308173 TRIM28 biliary tract,bile duct,carcinoma,NS c.1475G>T p.R492L 19:58549053-58549053 11
10 COSM44463 TP53 biliary tract,bile duct,carcinoma,NS c.848G>T p.R283L 17:7673772-7673772 11
11 COSM43687 TP53 biliary tract,bile duct,carcinoma,NS c.641A>G p.H214R 17:7674890-7674890 11
12 COSM10687 TP53 biliary tract,bile duct,carcinoma,NS c.527G>A p.C176Y 17:7675085-7675085 11
13 COSM10731 TP53 biliary tract,bile duct,carcinoma,NS c.707A>G p.Y236C 17:7674256-7674256 11
14 COSM10662 TP53 biliary tract,bile duct,carcinoma,NS c.743G>A p.R248Q 17:7674220-7674220 11
15 COSM11073 TP53 biliary tract,bile duct,carcinoma,NS c.1024C>T p.R342* 17:7670685-7670685 11
16 COSM43751 TP53 biliary tract,bile duct,carcinoma,NS c.673-1G>A p.? 17:7674291-7674291 11
17 COSM44918 TP53 biliary tract,bile duct,carcinoma,NS c.844C>A p.R282R 17:7673776-7673776 11
18 COSM44240 TP53 biliary tract,bile duct,carcinoma,NS c.514G>T p.V172F 17:7675098-7675098 11
19 COSM10704 TP53 biliary tract,bile duct,carcinoma,NS c.844C>T p.R282W 17:7673776-7673776 11
20 COSM22908 TP53 biliary tract,bile duct,carcinoma,NS c.376-1G>T p.? 17:7675237-7675237 11
21 COSM44143 TP53 biliary tract,bile duct,carcinoma,NS c.919+1G>A p.? 17:7673700-7673700 11
22 COSM43836 TP53 biliary tract,bile duct,carcinoma,NS c.475G>C p.A159P 17:7675137-7675137 11
23 COSM10742 TP53 biliary tract,bile duct,carcinoma,NS c.578A>G p.H193R 17:7674953-7674953 11
24 COSM1522202 TP53 biliary tract,bile duct,carcinoma,NS c.1051A>T p.K351* 17:7670658-7670658 11
25 COSM10727 TP53 biliary tract,bile duct,carcinoma,NS c.438G>A p.W146* 17:7675174-7675174 11
26 COSM44786 TP53 biliary tract,bile duct,carcinoma,NS c.694A>C p.I232L 17:7674269-7674269 11
27 COSM10648 TP53 biliary tract,bile duct,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 11
28 COSM10660 TP53 biliary tract,bile duct,carcinoma,NS c.818G>A p.R273H 17:7673802-7673802 11
29 COSM43596 TP53 biliary tract,bile duct,carcinoma,NS c.841G>A p.D281N 17:7673779-7673779 11
30 COSM43909 TP53 biliary tract,bile duct,carcinoma,NS c.817C>A p.R273S 17:7673803-7673803 11
31 COSM11090 TP53 biliary tract,bile duct,carcinoma,NS c.541C>T p.R181C 17:7675071-7675071 11
32 COSM6917440 TP53 biliary tract,bile duct,carcinoma,NS c.736A>C p.M246L 17:7674227-7674227 11
33 COSM6081949 TP53 biliary tract,bile duct,carcinoma,NS c.1060C>T p.Q354* 17:7670649-7670649 11
34 COSM10690 TP53 biliary tract,bile duct,carcinoma,NS c.473G>A p.R158H 17:7675139-7675139 11
35 COSM10656 TP53 biliary tract,bile duct,carcinoma,NS c.742C>T p.R248W 17:7674221-7674221 11
36 COSM10645 TP53 biliary tract,bile duct,carcinoma,NS c.527G>T p.C176F 17:7675085-7675085 11
37 COSM11071 TP53 biliary tract,bile duct,carcinoma,NS c.1009C>T p.R337C 17:7670700-7670700 11
38 COSM10749 TP53 biliary tract,bile duct,carcinoma,NS c.830G>T p.C277F 17:7673790-7673790 11
39 COSM44151 TP53 biliary tract,bile duct,carcinoma,NS c.535C>A p.H179N 17:7675077-7675077 11
40 COSM44262 TP53 biliary tract,bile duct,carcinoma,NS c.808T>C p.F270L 17:7673812-7673812 11
41 COSM11078 TP53 biliary tract,bile duct,carcinoma,NS c.1027G>T p.E343* 17:7670682-7670682 11
42 COSM10659 TP53 biliary tract,bile duct,carcinoma,NS c.817C>T p.R273C 17:7673803-7673803 11
43 COSM43947 TP53 biliary tract,bile duct,carcinoma,NS c.614A>G p.Y205C 17:7674917-7674917 11
44 COSM10883 TP53 biliary tract,bile duct,carcinoma,NS c.731G>A p.G244D 17:7674232-7674232 11
45 COSM44523 TP53 biliary tract,bile duct,carcinoma,NS c.863A>G p.N288S 17:7673757-7673757 11
46 COSM10672 TP53 biliary tract,bile duct,carcinoma,NS c.577C>T p.H193Y 17:7674954-7674954 11
47 COSM11355 TP53 biliary tract,bile duct,carcinoma,NS c.737T>C p.M246T 17:7674226-7674226 11
48 COSM44226 TP53 biliary tract,bile duct,carcinoma,NS c.380C>T p.S127F 17:7675232-7675232 11
49 COSM10725 TP53 biliary tract,bile duct,carcinoma,NS c.701A>G p.Y234C 17:7674262-7674262 11
50 COSM43850 TP53 biliary tract,bile duct,carcinoma,NS c.659A>C p.Y220S 17:7674872-7674872 11

Copy number variations for Cholangiocarcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 111150 17 35097918 35138441 Copy number ERBB2 Cholangiocarcinoma
2 118016 17 7512444 7519279 Copy number P53 Cholangiocarcinoma
3 159441 21 42600000 48129895 Amplification TFF1 Cholangiocarcinoma
4 159442 21 42600000 48129895 Amplification TFF2 Cholangiocarcinoma
5 159443 21 42600000 48129895 Amplification TFF3 Cholangiocarcinoma

Expression for Cholangiocarcinoma

Search GEO for disease gene expression data for Cholangiocarcinoma.

Pathways for Cholangiocarcinoma

Pathways related to Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.5 MIR141 MIR152 MIR200B MIR21 MIR373

GO Terms for Cholangiocarcinoma

Cellular components related to Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 MIR141 MIR148A MIR152 MIR204 MIR21 MIR320A
2 micro-ribonucleoprotein complex GO:0035068 9.32 H19 MIR141 MIR148A MIR152 MIR200B MIR204

Biological processes related to Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 miRNA mediated inhibition of translation GO:0035278 9.33 MIR148A MIR204 MIR21
2 gene silencing by miRNA GO:0035195 9.32 H19 MIR141 MIR148A MIR152 MIR200B MIR204
3 negative regulation of blood vessel endothelial cell migration GO:0043537 9.13 MIR152 MIR200B MIR204

Molecular functions related to Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.17 MIR141 MIR148A MIR152 MIR200B MIR204 MIR21

Sources for Cholangiocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....